Abstract

The aim of this study was to investigate the serotype-associated fatality rate in cases of invasive pneumococcal disease (IPD) in the Spanish region of Madrid between 2007 and 2020. Serotyping was performed by Pneumotest Latex and the Quellung reaction using commercial antisera. Case-fatality rate was estimated as the ratio between the number of deaths at hospital discharge and the number of cases attributable to each serotype. To evaluate the association measures, the odds ratios with a 95% confidence interval were calculated. Twenty five pneumococcal serotypes were associated to mortality and comprised 87.8% of the total number of isolates characterized. Serotypes 8, 3, 19A, 1, 7F, 22F, 12F, and 11A were the most prevalent (≥3% each). Serotypes 31, 11A, and 19F were significantly associated to high case-fatality rates (>20% each). The lower significantly associated case-fatality rate (<10% each) was found in serotypes 5, 1, 12B, 7F, 12F, 8, 33, and 10A. The serotypes with higher mortality levels (≥0.04 per 100,000 population) were 11A (fatality 24.0%), 3 (fatality 18.7%), 19A (fatality 12.5%), and 8 (fatality 7.2%). Serotype 3 was worrisome because it is associated with important fatality levels combined with very high incidence and mortality rates. Serotype 11A also showed a high fatality with marked incidence and mortality levels. Some few frequent serotypes as 31, 19F, and 15A despite its high fatality had low levels of mortality. By contrast other serotypes as 8 showing low fatality had high mortality ranges because it shows a wide extended distribution. Finally, common serotypes, such as 1 and 5, presented small mortality length, due to their low case-fatality rates.

Highlights

  • From 2009–2011, it was replaced by new available conjugate vaccines against serotypes (PCV10, adding to PCV7 the serotypes 1, 5, 7F) and 13 serotypes (PCV13, adding to PCV10 serotypes 3, 6A, and 19A)

  • Fatality was defined as an invasive pneumococcal disease (IPD)-related death that are fatal within 28 days of onset

  • A long-term period of 13 years was monitored for IPD in Madrid to analyze mortality by serotypes [9]

Read more

Summary

Introduction

In 2001, the seven-valent pneumococcal conjugate vaccine (PCV7) comprising serotypes. 4, 6B, 9V, 14, 18C, 19F, and 23F was approved for pediatric use in Europe. From 2006–2008, it was introduced into the national pediatric immunization programs for many European countries. From 2009–2011, it was replaced by new available conjugate vaccines against serotypes (PCV10, adding to PCV7 the serotypes 1, 5, 7F) and 13 serotypes (PCV13, adding to PCV10 serotypes 3, 6A, and 19A). PCV10 and PCV13: Findings from the PSERENADE Project. M.; Misegades, L.; Fleming-Dutra, K.E.; Ahmed, S.; Gierke, R.; Nanduri, S.A.; Healy, J.M.; Nguyen, D.T.; Carvalho, M.D.G.; Pimenta, F.; et al Pneumococcal Serotype 5 Colonization Prevalence Among Newly Arrived Unaccompanied.

Objectives
Methods
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.